Randomized trial of standard therapy with or without poly I:C in patients with superficial bladder cancer
โ Scribed by Nancy Kemeny; Alan Yagoda; Ying Wang; Kirk Field; Helen Wrobleski; Willet Whitmore
- Publisher
- John Wiley and Sons
- Year
- 1981
- Tongue
- English
- Weight
- 390 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Background: Topotecan is a new antineoplastic agent with a broad spectrum of activity. the purpose of this phase i trial was to define the maximum tolerated dose of topotecan when added to the widely used combination of paclitaxel and carboplatin. ## Methods: Patients with advanced cancer that
Conventional external beam irradiation, using modern megavoltage techniques and doses that do not harm bladder function, will permanently eradicate local bladder cancer in 30% to 50% of patients, compared with 70% to 90% with cystectomy. In appropriately chosen patients, open surgery can safely prov
The excretion of nitrate, nitrite, apparent total N-nitroso compounds and volatile nitrosamines was measured in 24 hr urine from 61 Egyptians, divided into 4 groups: controls, Schistosoma haematobium-infected patients and bladder cancer patients with and without a history of schistosomal infection.